TS1

Prodigy Technovations announces innovative PCIeGen3/4 Protocol Analyzer

Retrieved on: 
Wednesday, September 14, 2022
Trigger, Software, TLP, Time, Industry, Protocol, G, TS1, Evaluation, Embedded, TS2, Protocol analyzer, Internet service provider, PCI Express

Ltd , a Bangalore-based company, introduces its PGY-PCIeGen3/4-PA PCIe Protocol Analyzer supporting 2.5, 5.0.

Key Points: 
  • Ltd , a Bangalore-based company, introduces its PGY-PCIeGen3/4-PA PCIe Protocol Analyzer supporting 2.5, 5.0.
  • PCIeGen3/4 Protocol Analyzer is used for development and validation of PCIe interface for M.2, U.2 and Embedded PCIe Bus.
  • PCIe Protocol Analyzer supports trigger on content of the protocol packets and if-then-elseif multi-level trigger capability.
  • Simultaneous Protocol analysis of 2.5, 5, 8, and 16GT/S Protocol Traffic
    Acquisition memory management to capture protocol traffic using trigger, segmented memory, circular buffer and hardware filters
    Simple and advanced Trigger based on TS1, TS2, DLLP and TLP Protocol packet content
    The PGY-PCIeGen3/4-PA , is now orderable.

Prodigy Technovations announces innovative PCIeGen3/4 Protocol Analyzer

Retrieved on: 
Wednesday, September 14, 2022
Trigger, Software, TLP, Time, Industry, Protocol, G, TS1, Evaluation, Embedded, TS2, Protocol analyzer, Internet service provider, PCI Express

Ltd , a Bangalore-based company, introduces its PGY-PCIeGen3/4-PA PCIe Protocol Analyzer supporting 2.5, 5.0.

Key Points: 
  • Ltd , a Bangalore-based company, introduces its PGY-PCIeGen3/4-PA PCIe Protocol Analyzer supporting 2.5, 5.0.
  • PCIeGen3/4 Protocol Analyzer is used for development and validation of PCIe interface for M.2, U.2 and Embedded PCIe Bus.
  • PCIe Protocol Analyzer supports trigger on content of the protocol packets and if-then-elseif multi-level trigger capability.
  • Simultaneous Protocol analysis of 2.5, 5, 8, and 16GT/S Protocol Traffic
    Acquisition memory management to capture protocol traffic using trigger, segmented memory, circular buffer and hardware filters
    Simple and advanced Trigger based on TS1, TS2, DLLP and TLP Protocol packet content
    The PGY-PCIeGen3/4-PA , is now orderable.

Samsung Bioepis Presents New Phase 3 Study of SB12 (Eculizumab), A Proposed Biosimilar to Soliris, at the European Hematology Association (EHA) Congress 2022

Retrieved on: 
Friday, June 10, 2022
Science, PNH, PK, Neuromyelitis optica spectrum disorder, ECU, Week, Hematology, LinkedIn, Pharmacokinetics, Ahus, European Hematology Association, Acetylcholine receptor, TS1, Ophthalmology, Endocrinology, Patient, GLOBE, LDH, DNA, TS2, EHA, Social media, Twitter, Paroxysmal nocturnal hemoglobinuria, Gastroenterology, PD, GMG, Microdeletion syndrome, Degenerative disease, Eculizumab, NMOSD, Safety, Generic drug, Pharmaceutical industry

The Phase 3 study results are presented as an e-poster at the 27th European Hematology Association 2022 (EHA2022) Hybrid Congress held in Vienna, Austria and virtually, from June 9 to 12, 2022.

Key Points: 
  • The Phase 3 study results are presented as an e-poster at the 27th European Hematology Association 2022 (EHA2022) Hybrid Congress held in Vienna, Austria and virtually, from June 9 to 12, 2022.
  • Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone.
  • Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company.
  • Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, endocrinology and gastroenterology.